Product Defect

Quinapril HCI/Hydrochlorothiazide Recall Investigation

Migliaccio & Rathod is currently investigating Pfizer’s recall of blood pressure medication Accuretic, for containing the known carcinogen N-nitroso-quinapril, a nitrosamine, in amounts that exceed Acceptable Daily Intake (ADI) levels. The recall also includes two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide). Prolonged exposure to nitrosamines above acceptable levels over time increases the patient’s risk of developing cancer. Pfizer currently advises patients taking this medication to consult with their doctors and switch to another blood pressure medication. The affected product lots are reproduced below:

Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 10/12.5 mg
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/12.5 mg
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/25 mg

NDC Lot Number Expiration Date Strength Configuration/Count
0071-3112-23
FG5379
08/2024 10/12.5 mg 1 x 90 count bottle
0071-0222-23
EA6686
04/2022 10/12.5 mg 1 x 90 count bottle
0071-5212-23
FG5381
08/2024 20/12.5 mg 1 x 90 count bottle
0071-0220-23
EA6665
04/2022 20/12.5 mg 1 x 90 count bottle
0071-0220-23
CN0640
04/2022 20/12.5 mg 1 x 90 count bottle
0071-0223-23
ET6974
02/2023 20/25 mg 1 x 90 count bottle

quinapril and hydrochlorothiazide tablets, 20/25 mg
quinapril HCl/hydrochlorothiazide tablets, 20/12.5 mg
quinapril HCl/hydrochlorothiazide tablets, 20/25 mg

NDC Lot Number Expiration Date Strength Configuration/Count
59762-5225-9
FE3714
02/2023 20/25 mg 1 x 90 count bottle
59762-0220-1
DN6931
03/2023 20/12.5 mg 1 x 90 count bottle
59762-0220-1
ED3904
03/2023 20/12.5 mg 1 x 90 count bottle
59762-0220-1
ED3905
03/2023 20/12.5 mg 1 x 90 count bottle
59762-0223-1
DP3414
02/2023 20/25 mg 1 x 90 count bottle

UPDATE (4/25/2022): Pfizer Inc. is recalling several lots of a blood pressure drug due to elevated levels of a potential cancer-causing impurity.

The recalled product lots were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from December 2019 to April 2022, according to the FDA notice. The impacted products include:

Accupril® (Quinapril HCl Tablets), 10 mg

Accupril® (Quinapril HCl Tablets), 20 mg

Accupril® (Quinapril HCl Tablets), 40 mg

Did you take medicines containing quinapril and were you notified of the FDA’s recall?

If so, we would like to hear from you. Please complete the contact form on this page, send us an email at info@classlawdc.com, or call us at (202) 470-3520 for more information.

Committed to Consumer Protection

The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving data breaches and product defects. More information about our current cases and investigations is available on our blog.

Facebooktwitterlinkedinmail